Through inhibiting cancer cell ferroptosis in a PI3K‐Akt‐dependent manner, ANO1 stimulates the production and secretion of TGF‐β by cancer cells, subsequently strengthens cancer‐associated fibroblast recruitment, and cripples CD8+ T cell‐mediated anti‐tumor immune responses, generating resistance to immunotherapy. Here, TGFB1 is linked to neoplasm.